DOCSLIB.ORG

691.Full.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
691.Full.Pdf Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis This information is current as Rui Li, Ayman Rezk, Mathab Ghadiri, Felix Luessi, Frauke of September 29, 2021. Zipp, Hulun Li, Paul S. Giacomini, Jack Antel and Amit Bar-Or J Immunol 2017; 198:691-698; Prepublished online 14 December 2016; doi: 10.4049/jimmunol.1601649 Downloaded from http://www.jimmunol.org/content/198/2/691 Supplementary http://www.jimmunol.org/content/suppl/2016/12/14/jimmunol.160164 Material 9.DCSupplemental http://www.jimmunol.org/ References This article cites 32 articles, 8 of which you can access for free at: http://www.jimmunol.org/content/198/2/691.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 29, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts Errata An erratum has been published regarding this article. Please see next page or: /content/202/7/2172.full.pdf The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis Rui Li,* Ayman Rezk,* Mathab Ghadiri,* Felix Luessi,*,† Frauke Zipp,† Hulun Li,‡ Paul S. Giacomini,* Jack Antel,* and Amit Bar-Or* The therapeutic mode of action of dimethyl fumarate (DMF), approved for treating patients with relapsing-remitting multiple sclerosis, is not fully understood. Recently, we and others demonstrated that Ab-independent functions of distinct B cell subsets are important in mediating multiple sclerosis (MS) relapsing disease activity. Our objective was to test whether and how DMF influences both the phenotype and functional responses of disease-implicated B cell subsets in patients with MS. High-quality PBMC were obtained from relapsing-remitting MS patients prior to and serially after initiation of DMF treatment. Multiparametric flow Downloaded from cytometry was used to monitor the phenotype and functional response-profiles of distinct B cell subsets. Total B cell counts decreased following DMF treatment, largely reflecting losses of circulating mature/differentiated (but not of immature transitional) B cells. Within the mature B cell pool, DMF had a greater impact on memory than naive B cells. In keeping with these in vivo effects, DMF treatment in vitro remarkably diminished mature (but not transitional B cell) survival, mediated by inducing apoptotic cell death. Although DMF treatment (both in vivo and in vitro) minimally impacted B cell IL-10 expression, it strongly reduced B cell ex- pression of GM-CSF, IL-6, and TNF-a, resulting in a significant anti-inflammatory shift of B cell response profiles. The DMF- http://www.jimmunol.org/ mediated decrease in B cell proinflammatory cytokine responses was further associated with reduced phosphorylation of STAT5/6 and NF-kB in surviving B cells. Together, these data implicate novel mechanisms by which DMF may modulate MS disease activity through shifting the balance between pro- and anti-inflammatory B cell responses. The Journal of Immunology, 2017, 198: 691–698. ultiple sclerosis (MS) is a chronic inflammatory demy- tively little is known about the impact of DMF on B cell subset elinating disease of the CNS (1). An imbalance between responses, which are now strongly implicated in relapsing MS M proinflammatory immune effectors and anti-inflammatory disease activity based on the clinical success of B cell depleting by guest on September 29, 2021 immune regulators has been implicated in MS disease pathogenesis, therapy. with a traditional focus on the role of particular T cell subsets (1). Interestingly, B cell depletion using anti-CD20 monoclonal Abs Oral dimethyl fumarate (DMF) has been recently approved for treat- effectively decreased MS disease activities without apparently ing patients with relapsing-remitting MS (RRMS) (2–4), yet the affecting the abnormal Ab levels in the CSF of MS patients (12– mode of action for DMF is still not fully understood. Although 15), suggesting that secreting pathogenic autoantibodies may emerging evidence has suggested that DMF can downregulate not be the primary mechanism by which B cells contribute T cell and myeloid cell proinflammatory responses (5–11), rela- to MS relapses. Indeed, we and others have shown that Ab- independent functions of B cells, such as Ag presentation and production of proinflammatory cytokines by functionally dis- *Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Mon- tinct B cell subsets, are important contributors to MS disease † treal, Quebec H3A 2B4, Canada; Department of Neurology, Focus Program Trans- activity (16–23). lational Neuroscience and Immunotherapy, Rhine-Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, Mainz In this study we examined whether and how DMF may influence 55131, Germany; and ‡Department of Neurobiology, Harbin Medical University, both the phenotypes and functional response profiles of distinct NanGang District, Harbin 150086, Heilongjiang, China B cell subsets. We show that total B cell counts diminish substan- ORCIDs: 0000-0003-3594-4880 (M.G.); 0000-0002-1231-1928 (F.Z.); 0000-0002- tially following the initiation of DMF treatment, a decrease that 1346-3042 (P.S.G.). largely reflects the loss of circulating differentiated but not of Received for publication September 22, 2016. Accepted for publication November 14, 2016. immature transitional B cells in treated patients. In vitro treatment This work was supported by the research foundation of the Multiple Sclerosis Society with DMF mirrored the in vivo effects, directly inducing mature of Canada (A.B.-O.), Banque National Fellowship (R.L.), and National Natural Sci- B cell but not transitional B cell apoptosis. The functional analysis ence Foundation (Grant 81430035, R.L. and H.L.). further revealed that treatment with DMF (both in vivo and Address correspondence and reprint requests to Prof. Amit Bar-Or, Neuroimmunol- in vitro) decreased B cell expression of proinflammatory (GM-CSF, ogy Unit and Experimental Therapeutics Program, Montreal Neurological Institute a and Hospital, McGill University, 3801 University Street, Room 123, Montreal, QC IL-6, and TNF- ) but minimally impacted anti-inflammatory H3A 2B4, Canada. E-mail address: [email protected] (IL-10) B cell response profiles, associated not only with prefer- The online version of this article contains supplemental material. ential apoptosis, but also with reduced phosphorylation of STAT5/6 Abbreviations used in this article: DMF, dimethyl fumarate; HC, healthy control; and NF-kB in surviving B cells. Our study suggests that the ca- ICS, intracellular cytokine staining; MMF, monomethyl fumarate; MS, multiple scle- pacity of DMF to limit new MS inflammatory disease activity may, rosis; PI, propidium iodide; RRMS, relapsing-remitting MS. in part, relate to its ability to mediate an anti-inflammatory shift in Copyright Ó 2017 by The American Association of Immunologists, Inc. 0022-1767/17/$30.00 the balance of phenotypically and functionally distinct B cell subsets. www.jimmunol.org/cgi/doi/10.4049/jimmunol.1601649 692 DMF REGULATES THE BALANCE OF B CELL SUBSETS IN MS PATIENTS interassay variability. Where indicated, magnetic bead sorting (Miltenyi Materials and Methods + Subjects and study design Biotec) was used to positively select CD19 B cells from fresh PBMC with purities routinely .98% as confirmed by flow cytometry. Isolated B cells A total of 13 patients (11 females, 2 males) with McDonald criteria– were plated in U-bottom 96-well plates at 2 3 105/well in a total volume of confirmed RRMS, mean age 41 (range 20–60), were prospectively fol- 200 ml of serum-free x-vivo medium (Lonza), and stimulated with soluble lowed at a single center in Montreal, Canada, prior to and following CD40L (1 mg/ml; Enzo Life Sciences), goat anti-human BCR cross- treatment initiation with DMF. Patients were assessed every 3 mo with linking Ab (Xab) (10 mg/ml; Jackson ImmunoResearch) with or without clinical review, physical examination, and expanded disability status score. IL-4 (20 ng/ml; R&D Systems) for 48 h, at which time supernatants were At study entry, patients had an average expanded disability status score of collected and frozen (270) for subsequent quantification of cytokine secretion 2.5 (range 1.0–4.0), preceding annualized relapse rate of 0.8 (0–2), and by ELISA and the cells were analyzed by flow cytometry (as described be- disease duration of 9.6 y (range 1–27 y). Of the 13 patients, 11 had pre- low). B cells were cultured in parallel wells in either medium alone, vehicle viously been treated with either IFN or glatiramer acetate, one had re- (DMSO), monomethyl fumarate (MMF), or DMF (Sigma Aldrich, Oakville, ceived a single dose of ofatumumab 18 mo prior to recruitment,
Load more

Recommended publications
  • SAHLGRENSKA AKADEMIN Thymic Studies
    Göteborg, 2019 Thymic studies Investigations into the effects of childhood thymectomy, and characterization of thymic B cells and Hassall's corpuscles Akademisk avhandling Som för avläggande av medicine doktorsexamen vid Sahlgrenska akademin, Göteborgs universitet kommer att offentligen försvaras i föreläsningssalen våning 3, Guldhedsgatan 10A, Göteborg Tisdagen den 14e maj, klockan 13.00 av Christina Lundqvist Fakultetsopponent: Professor Ludger Klein Ludwig-Maximilians-Universität, Tyskland Avhandlingen baseras på följande delarbeten I. Gudmundsdottir J*, Lundqvist C*, Ijspeert H, van der Slik E, Óskarsdóttir S, Lindgren S, Lundberg V, Berglund M, Lingman-Framme J, Telemo E, van der Burg M, Ekwall O. T-cell receptor sequencing reveals decreased diversity 18 years after early thymectomy. J Allergy Clin Immunol. 2017 Dec;140(6):1743- 1746.e7. doi: 10.1016/j.jaci.2017.08.002. Epub 2017 Sep 1. * These authors contributed equally to this work. II. Lundqvist C*, Camponeschi A*, Visentini M, Telemo E, Ekwall O‡, Mårtensson IL‡. Switched CD21-/low B cells with an antigen-presenting phenotype in the infant thymus. J Allergy Clin Immunol. 2018 Nov 30. pii: S0091-6749(18)31721- 4. doi: 10.1016/j.jaci.2018.11.019. * These authors contributed equally to this work. ‡ These authors contributed equally to this work. III. Lundqvist C, Lindgren S, Cheuk S, Lundberg V, Berglund M, Thörn K, Telemo E, Ekwall O. Characterization of Hassall's corpuscles in the human thymus. Manuscript SAHLGRENSKA AKADEMIN INSTITUTIONEN FÖR MEDICIN Göteborg, 2019 Thymic studies Investigations into the effects of childhood thymectomy, and characterization of thymic B cells and Hassall's corpuscles Christina Lundqvist Avdelningen för reumatologi och inflammationsforskning, Institutionen för medicin, Sahlgrenska akademin, Göteborgs universitet Abstract This thesis focuses on the human thymus, a primary lymphoid organ responsible for the maturation of T cells.
    [Show full text]
  • B Cells + Interaction
    Human B Cell Activation by Autologous NK Cells Is Regulated by CD40-CD40 Ligand Interaction: Role of Memory B Cells and CD5 + B Cells This information is current as of October 2, 2021. Isaac R. Blanca, Earl W. Bere, Howard A. Young and John R. Ortaldo J Immunol 2001; 167:6132-6139; ; doi: 10.4049/jimmunol.167.11.6132 http://www.jimmunol.org/content/167/11/6132 Downloaded from References This article cites 45 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/167/11/6132.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Human B Cell Activation by Autologous NK Cells Is Regulated by CD40-CD40 Ligand Interaction: Role of Memory B Cells and CD5؉ B Cells Isaac R. Blanca,*† Earl W. Bere,* Howard A.
    [Show full text]
  • Advanced Laboratory Studies for Primary Immunodeficiency Disorders
    4813: Problem-based Learning Workshop Advanced Laboratory studies for Primary Immunodeficiency Disorders Moderator: Richard Wasserman, MD, PhD Discussion Leader: Roshini Abraham, PhD ● Understand B cell flow analysis in CVID (PBL case) HUMAN PERIPHERAL B CELL DIFFERENTIATION Marginal zone B cells Bone marrow Immature B cells Transitional B cells Naïve B cells Memory B cells Plasmablasts Periphery MARKERS FOR PERIPHERAL B CELL SUBSETS - CURRENT Total B cells: CD19 and/or CD20 Transitional B cells: CD19+CD38+IgM+ Total IgM+ B cells: CD19+IgM+ (includes naïve B cells) Memory B cells: CD19+CD27+ switched memory B cells: CD19+CD27+IgM-IgD- marginal zone B cells: CD19+CD27+IgM+IgD+ IgM-only memory B cells: CD19+CD27+IgM+IgD- Plasmablasts: CD19+CD38+IgM- CD21+ B cells: CD19+CD21+ CD21- B cells: CD19+CD21- ● With newer information, more suitable cellular markers are available for accurate identification of transitional B cells and plasmablasts, in particular, but also for naïve B cells NEWER B CELL MARKERS FOR B CELL SUBSET QUANTITATION Total B cells and B cell subsets can be quantitated in blood using multicolor flow cytometry: Total B cells: CD45+CD19+20+ For B cell subset analysis, the gating strategy uses CD45+19+20+/- (depending on the subset being studied), thus these markers are not specifically repeated in the panel below:- Transitional B cells: T1: CD24hi38hi10+27-21lowIgM+++ T2: CD24hi38hi10+27-21int IgM+++ Naïve B cells: IgM+IgD+27-38-21+++ Memory B cells: Marginal zone B cells: CD27+IgM+IgD+ IgM-only memory: CD27+IgM+IgD- IgD-only
    [Show full text]
  • Vaccine Immunology Claire-Anne Siegrist
    2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.
    [Show full text]
  • B-Cell Development, Activation, and Differentiation
    B-Cell Development, Activation, and Differentiation Sarah Holstein, MD, PhD Nov 13, 2014 Lymphoid tissues • Primary – Bone marrow – Thymus • Secondary – Lymph nodes – Spleen – Tonsils – Lymphoid tissue within GI and respiratory tracts Overview of B cell development • B cells are generated in the bone marrow • Takes 1-2 weeks to develop from hematopoietic stem cells to mature B cells • Sequence of expression of cell surface receptor and adhesion molecules which allows for differentiation of B cells, proliferation at various stages, and movement within the bone marrow microenvironment • Immature B cell leaves the bone marrow and undergoes further differentiation • Immune system must create a repertoire of receptors capable of recognizing a large array of antigens while at the same time eliminating self-reactive B cells Overview of B cell development • Early B cell development constitutes the steps that lead to B cell commitment and expression of surface immunoglobulin, production of mature B cells • Mature B cells leave the bone marrow and migrate to secondary lymphoid tissues • B cells then interact with exogenous antigen and/or T helper cells = antigen- dependent phase Overview of B cells Hematopoiesis • Hematopoietic stem cells (HSCs) source of all blood cells • Blood-forming cells first found in the yolk sac (primarily primitive rbc production) • HSCs arise in distal aorta ~3-4 weeks • HSCs migrate to the liver (primary site of hematopoiesis after 6 wks gestation) • Bone marrow hematopoiesis starts ~5 months of gestation Role of bone
    [Show full text]
  • B Cell Responses Against Influenza Viruses
    viruses Review B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat Jenna J. Guthmiller 1,* , Henry A. Utset 1 and Patrick C. Wilson 1,2 1 Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA; [email protected] (H.A.U.); [email protected] (P.C.W.) 2 Committee on Immunology, University of Chicago, Chicago, IL 60637, USA * Correspondence: [email protected] Abstract: Antibodies are critical for providing protection against influenza virus infections. However, protective humoral immunity against influenza viruses is limited by the antigenic drift and shift of the major surface glycoproteins, hemagglutinin and neuraminidase. Importantly, people are exposed to influenza viruses throughout their life and tend to reuse memory B cells from prior exposure to generate antibodies against new variants. Despite this, people tend to recall memory B cells against constantly evolving variable epitopes or non-protective antigens, as opposed to recalling them against broadly neutralizing epitopes of hemagglutinin. In this review, we discuss the factors that impact the generation and recall of memory B cells against distinct viral antigens, as well as the immunological limitations preventing broadly neutralizing antibody responses. Lastly, we discuss how next-generation vaccine platforms can potentially overcome these obstacles to generate robust and long-lived protection against influenza A viruses. Keywords: influenza viruses; humoral immunity; broadly neutralizing antibodies; imprinting; Citation: Guthmiller, J.J.; Utset, H.A.; hemagglutinin; germinal center; plasma cells Wilson, P.C. B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat. Viruses 2021, 13, 1.
    [Show full text]
  • Evasion of Affinity-Based Selection in Germinal Centers by Epstein–Barr Virus LMP2A
    Evasion of affinity-based selection in germinal centers by Epstein–Barr virus LMP2A Takeharu Minamitania,1, Teruhito Yasuia,1,2, Yijie Mab, Hufeng Zhoub, Daisuke Okuzakic, Chiau-Yuang Tsaia, Shuhei Sakakibaraa, Benjamin E. Gewurzb, Elliott Kieffb,2, and Hitoshi Kikutania,2 aDepartment of Molecular Immunology, Research Institute for Microbial Diseases, World Premier International Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan; bDivision of Infectious Disease, Department of Medicine, Microbiology and Immunobiology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115; and cDNA-chip Development Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan Contributed by Elliott Kieff, July 27, 2015 (sent for review May 1, 2015) Epstein–Barr virus (EBV) infects germinal center (GC) B cells and B-cell development or augments the differentiation and acti- establishes persistent infection in memory B cells. EBV-infected B vation of antigen-driven B cells (9, 10, 14–16). cells can cause B-cell malignancies in humans with T- or natural In the peripheral blood of persistently infected people, EBV − killer-cell deficiency. We now find that EBV-encoded latent mem- resides exclusively in IgD memory B cells (17). However, in ton- brane protein 2A (LMP2A) mimics B-cell antigen receptor (BCR) signal- sils, EBV is found not only in memory B cells but also in GC and + ing in murine GC B cells, causing altered humoral immune responses IgD resting B cells in which EBNA1, LMP1, and LMP2A are and autoimmune diseases. Investigation of the impact of LMP2A on expressed (17, 18).
    [Show full text]
  • An Overview of B Cells – from Discovery to Therapy Mini Review
    An Overview of B Cells – from Discovery to Therapy Mini Review Immunology In the past two decades, significant advances have been made in B cell biology. These critical immune cells remain an active area of research particularly because disruption of B cell development or function results in a number of autoimmune diseases and malignancies. In addition to producing antibodies, B cells are professional antigen presenting cells that can present antigens to T cells to generate effective immune responses. B cells are however, a heterogeneous population of cells at different stages of maturation along the lineage, each with unique functional properties. This mini-review provides a brief history of the discovery of B cells, as well as describes the characteristics of each B cell lineage and the processes of B cell development, maturation and activation. Finally, we highlight the application of B cell biology in the development of novel therapeutics for the treatment of B cell mediated diseases. Contents 1. A brief history of the discovery of B cells 2. B cell development and maturation 3. B cell activation and the humoral immune response 4. B cells as therapeutic targets 1. A brief history of the discovery of B cells B cells are an integral part of the adaptive immune response. They represent a distinct lineage, with separate and unique functions from T cells. In addition to producing antibodies, they perform critical immune functions such as generating immunological memory, antigen presentation and regulatory cytokine production. Our current understanding of B cell biology was initiated in 1965 with a landmark study by Max Cooper and Robert Good.
    [Show full text]
  • Pathogen Manipulation of B Cells: the Best Defence Is a Good Offence
    REVIEWS Pathogen manipulation of B cells: the best defence is a good offence Katharina Nothelfer1–3, Philippe J. Sansonetti1,2,4 and Armelle Phalipon1,2 Abstract | B cells have long been regarded as simple antibody production units, but are now becoming known as key players in both adaptive and innate immune responses. However, several bacteria, viruses and parasites have evolved the ability to manipulate B cell functions to modulate immune responses. Pathogens can affect B cells indirectly, by attacking innate immune cells and altering the cytokine environment, and can also target B cells directly, impairing B cell-mediated immune responses. In this Review, we provide a summary of recent advances in elucidating direct B cell–pathogen interactions and highlight how targeting this specific cell population benefits different pathogens. pattern recognition receptors 4–6 (FIG. 1) Immunoglobulin B cells are essential components of the adaptive immune general (PRRs) . The A large, Y‑shaped protein that system, and they were first defined and distinguished activation of several B cell clones (termed polyclonal is produced by B cells. from T cells almost 50 years ago1. Both B cells and T cells B cell activation) and their subsequent differentiation Immunoglobulins exist in a recognize pathogens with antigen-specific receptors, into short-lived plasma cells results in the production membrane-bound form as B cell receptors or are secreted but they differ in their developmental pathways and of low-specificity antibodies, which are generally asso- as antibodies. functions during infections. T cells differentiate in the ciated with the beneficial effects of an early weakening thymus and orchestrate immune responses as CD4+ of infections7.
    [Show full text]
  • B Cells, Ig, Aging and Inflammation Bonnie B. Blomberg
    Immunology of aging #1: Why older adults are at increased risk of vaccine-preventable diseases Bonnie B. Blomberg Dept. of Microbiology and Immunology U Miami Miller School of Medicine Immunization in the elderly World Health Organization March 22-23, 2017 WHO Objectives: 1) Discuss the immunologic basis for why susceptibility to vaccine preventable diseases increases with age. 2) Discuss the immunologic basis for why response to vaccination decreases with age 3) Present possible mechanisms for these effects with our data on the molecular and cellular mechanisms affecting B cells and chronic inflammation in the elderly Franco Ferracci, Ryan Thomas, Acknowledgements Nick Mendez Mitch Phillips, John Ryan, Robert Schwartz, Family Medicine Sandra Chen, Daniela Frasca Env. Health & Safety Alain Diaz Bali Pulendran & Helder Maria Romero Nakaya (Emory) Thomas Vazquez Hana Golding & Surender Khurana (FDA) Giuseppe del Guidice Richard Riley (Novartis) NIH-NIA, R37 AG023717 (BBB) Mike Antoni NIH-NIA, R01 AG032576 (BBB)NIH- Suzanne Lechner NIAID, R21 AI096446 (BBB+DF) FL Bankhead Coley Cancer Res Prog. (Antoni-Blomberg), 6/1/2016-5/31/2021 NIH (Penedo) NCI R01 CA206456 (collab. With Antoni and All the subjects! Northwestern) 7/01/2016 – 06/30/2021 OUTLINE - Introduction to Aging and Immune defects - Summary of our previous results for Influenza vaccine responses Biomarkers to predict the response: Sw Mem B, AID, low TNF-α - Measures of inflammation/obesity and B cell response - Conclusions, future directions Aging Immune System - 1 • In both mice and humans: • Decline in T cell (cellular) functions: – Thymus atrophy (involution) – Decline in T cell functions such as frequency of CD4+ T cells and mitogen activation Aging Immune System - 2 • In both mice and humans: • Decline in B cell (antibody) functions: – Diminished ability to generate high affinity protective antibody responses to immunization against infectious agents or experimental antigens.
    [Show full text]
  • Functional Capacities of Human Igm Memory B Cells in Early Inflammatory Responses and Secondary Germinal Center Reactions
    Functional capacities of human IgM memory B cells in early inflammatory responses and secondary germinal center reactions Marc Seiferta, Martina Przekopowitza, Sarah Taudiena, Anna Lolliesa, Viola Rongea, Britta Dreesa, Monika Lindemannb, Uwe Hillenc, Harald Englerd, Bernhard B. Singere, and Ralf Küppersa,1 aInstitute of Cell Biology (Cancer Research), bInstitute for Transfusion Medicine, cDepartment of Dermatology, dInstitute of Medical Psychology and Behavioural Immunobiology, and eInstitute of Anatomy, Medical Faculty, University of Duisburg-Essen, Essen 45122, Germany Edited* by Klaus Rajewsky, Max Delbruck Center for Molecular Medicine, Berlin, Germany, and approved December 30, 2014 (received for review August 22, 2014) The generation and functions of human peripheral blood (PB) IgM+ (BCRs) that are expressed on post-GC memory B cells or se- + + IgD CD27 B lymphocytes with somatically mutated IgV genes are creted by long-lived PCs (7). Egress of these cells to the lymph controversially discussed. We determined their differential gene node medullary chords, red pulp, or bone marrow is mediated expression to naive B cells and to IgM-only and IgG+ memory B by chemokine (C-X-C motif) ligand 12 (CXCL12) / chemokine cells. This analysis revealed a high similarity of IgM+(IgD+)CD27+ (C-X-C motif) receptor 4 (CXCR4) (8). + and IgG memory B cells but also pointed at distinct functional Specificity and memory represent the hallmarks of adaptive capacities of both subsets. In vitro analyses revealed a tendency immunity. Memory B cells are generated in adaptive immune of activated IgM+IgD+CD27+ B cells to migrate to B-cell follicles and responses and confer enhanced and improved reactivity against undergo germinal center (GC) B-cell differentiation, whereas acti- recurring antigen.
    [Show full text]
  • The Bone Marrow As Sanctuary for Plasma Cells and Memory T-Cells: Implications for Adaptive Immunity and Vaccinology
    cells Review The Bone Marrow as Sanctuary for Plasma Cells and Memory T-Cells: Implications for Adaptive Immunity and Vaccinology Stefan A. Slamanig 1,2,† and Martijn A. Nolte 1,2,* 1 Department of Molecular Hematology, Sanquin Research, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands; [email protected] 2 Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands * Correspondence: [email protected] † Current address: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Abstract: The bone marrow (BM) is key to protective immunological memory because it harbors a major fraction of the body’s plasma cells, memory CD4+ and memory CD8+ T-cells. Despite its paramount significance for the human immune system, many aspects of how the BM enables decade-long immunity against pathogens are still poorly understood. In this review, we discuss the relationship between BM survival niches and long-lasting humoral immunity, how intrinsic and extrinsic factors define memory cell longevity and show that the BM is also capable of adopting many responsibilities of a secondary lymphoid organ. Additionally, with more and more data on the differentiation and maintenance of memory T-cells and plasma cells upon vaccination in humans being reported, we discuss what factors determine the establishment of long-lasting immunological memory in the BM and what we can learn for vaccination technologies and antigen design. Finally, using these insights, we touch on how this holistic understanding of the BM is necessary for the development of modern and efficient vaccines against the pandemic SARS-CoV-2. Citation: Slamanig, S.A.; Nolte, M.A.
    [Show full text]